Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) said CEO Barbara Weber, M.D. will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST / 12:45pm EST.
The presentation will be streamed live via the Investors > Events & Presentations page on the company's website, and a replay will be archived on the website for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – TNGX
In the Dec 17 session, TNGX declined 2.01%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | +1.8% | Announcement of participation in Piper Sandler healthcare conference with webcast replay. |
| Nov 12 | Conference participation | Neutral | -8.5% | Jefferies healthcare conference fireside chat announcement with webcast access. |
| Nov 04 | Earnings and pipeline | Positive | +0.0% | Q3 2025 profit, cash position, and multiple oncology program updates. |
| Oct 29 | Earnings notice | Neutral | +0.5% | Scheduling notice for Q3 2025 financial results release without conference call. |
| Oct 23 | Equity financing | Negative | -13.1% | Underwritten offering and PIPE totaling about $225M in gross proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Routine conference announcements have produced mixed reactions, while financing news aligned with a negative price move and positive earnings saw little immediate impact.
Over the last few months, Tango Therapeutics reported a profitable Q3 2025 driven by collaboration revenue and strengthened its balance sheet through approximately $225 million in October 2025 financing. Liquidity disclosures and a detailed Q3 10‑Q highlighted cash of $152.8M as of Sept 30, 2025 and a runway into 2028. At the same time, several conference and participation announcements, including healthcare conferences, generated varied short-term price reactions. Today’s J.P. Morgan conference participation fits within this pattern of ongoing investor outreach rather than a discrete clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
